期刊文献+

^(99m)Tc(Ⅳ)标记双膦酸配合物的制备及其在动物体内的骨显像性能 被引量:1

Preparation and in vivo Bone Imaging Properties of ^(99m)Tc(Ⅳ)-Labeled Diphosphonic Acid Complex
下载PDF
导出
摘要 以2-乙基咪唑、5-溴戊酸乙酯和PCl3为原料,合成了一种唑来膦酸衍生物:1-羟基-5-(2-乙基-1H-咪唑-1-基)戊烷-1,1-双膦酸(EIPeDP),将其与放射性元素99mTc(Ⅳ)进行标记形成配合物,研究了EIPeDP用量和反应体系pH值对标记率的影响。结果表明,当pH值为5~6、EIPeDP为5 mg、SnCl2.2H2O为100μg和Na99mTcO4为92.5 MBq时,可获得满意的标记率和放化纯(均大于97%)。标记物99mTc-EIPeDP具有良好的体外稳定性。动物体内实验表明,兔经注射99mTc-EIPeDP 1 h后获得的骨显像图质量明显优于99mTc-ZL和99mTc-MDP。表明99mTc-EIPeDP是一种制备简便、稳定性好和骨显像性能优异的新型放射显像剂。 A zoledronic acid derivative, 1-hydroxy-5-(2-ethyl-lH-irnidazol-l-yl) pentane-1, l-diphosphonic acid(EIPeDP), was synthesized using 2-ethylimidazole, 5-bromo valeric acid ethyl ester and PC13 as the starting material and further labeled with 99mTc. The influence of the amount of EIPeDP and the pH value of the reaction system on the labeling yield of 99mTc-EIPeDP has been studied. Satisfactory radiolabelling yield (RLY) and the radiochemical purity(RCP) (over 97% ) were obtained when the pH was 5 -6 and the amount of EIPeDP, SnC12 ~ 2H20 and Na99~ TcO4 were 5 mg, 100 I-~g and 92. 5 MBq, respectively. The radiolabeled complex was very stable in vitro. In vivo SPECT bone imaging of rabbit showed that a clearer image can be obtained from 99mTc-EIPeDP at 1 h post injection, which is superior to 99mTc-ZL and 99mTc-MDP. These results showed that 99mTc-EIPeDP is a potential bone imaging agent with advantages of simple preparation, good stabihty and superior bone imaging characteristics.
出处 《应用化学》 CAS CSCD 北大核心 2013年第5期542-548,共7页 Chinese Journal of Applied Chemistry
基金 国家自然科学基金(20801024) 江苏省自然科学基金(BK2009077) 江苏省医学重点人才基金(RC2011097)资助项目
关键词 唑来膦酸衍生物 99MTC标记 质控 稳定性 骨显像 zoledronic acid derivative, 99m Tc radiolabeling, quality control, stability, bone imaging
  • 相关文献

参考文献24

  • 1Palma E, ColTeia J D, CampeUo M P, et al. Bisphosphonates as Radionuclide Carriers for Imaging or Systemic Therapy [ J ]. Mol Biosyst,2011,7 :2950-2966.
  • 2Lin J H. Bisphosphonates : A Review of Their Pharmacokinetic Properties [ J ]. Bone, 1996,18:75-85.
  • 3吴明书,陈茹玉,黄有.双膦酸及其酯类化合物的合成研究进展[J].有机化学,2004,24(5):485-497. 被引量:20
  • 4郝二军,廉洁,苏永祥.唑来膦酸钠的合成工艺改进[J].化学试剂,2009,31(5):383-385. 被引量:10
  • 5Widler L,Jaeggi K A, Glatt M, et al. Highly Potent Geminal Bisphosphonates: From Pamidronate Disodium(Aredia) to Zoledronic Acid(Zometa) [ J]. J Med Chem,2002,45 ( 17 ) :3721-3738.
  • 6Russell R G G, Croucher P I, Rogers M J. Bisphosphonates : Pharmacology, Mechanisms of Action and Clinical Uses [ J ]. Osteoporos lnt, 1999,9 (2) : 66-80.
  • 7Teixeira F C, Antunes I F, Curto M J M, et al. Novel 1-Hydroxy-I, 1-Bisphosphonates Derived from Indazole:Synthesis and Characterization[ J]. Arkat USA Inc,2009:69-84.
  • 8Subramanian G, McAfee J G, Blair R J, et al. Technetium-99m-Methylene Diposphonate: a Superior Agent for Skeletal Imaging: Comparison with Other Technetium Complexes [ J ]. J Nucl Med, 1975,16:744-755.
  • 9Paes F M,Serafini A N. Systemic Metabolic Radiopharmaceutical Therapy in the Treatment of Metastatic Bone Pain[ J]. Semin Nucl Med,2010,40:89-104.
  • 10Lewington V J. Bone-Seeking Radionuclides for Therapy[J]. J Nucl Meal,2005,46( 1 ) :38S-47S.

二级参考文献49

共引文献50

同被引文献11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部